Bruker Corporation
HealthcareNASDAQ:BRKR · NASDAQ Global Select
-$1.47 today
Vol 1.60M · Avg 2.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$3.5B of revenue converted into -$11.6M of net income for the selected period. Gross margin is 45.6% and net margin is -0.4%, showing how much revenue survives after costs and taxes. EPS is $-0.24, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B +2.1% | $3.4B +13.6% | $3.0B +17.1% | $2.5B +4.7% | $2.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.9B +8.3% | $1.7B +18.3% | $1.5B +18.5% | $1.2B +1.4% | $1.2B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.6B -4.4% | $1.6B +9.0% | $1.5B +15.9% | $1.3B +7.9% | $1.2B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 45.9% -3.1pp | 49.0% -2.0pp | 51.0% -0.5pp | 51.6% +1.6pp | 50.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $395.2M +5.0% | $376.5M +27.7% | $294.8M +25.0% | $235.9M +6.8% | $220.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $946.5M +5.9% | $893.8M +22.5% | $729.4M +20.1% | $607.4M +8.0% | $562.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.3B -3.9% | $1.4B +29.7% | $1.1B +23.3% | $873.0M +9.6% | $796.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $220.3M +19.9% | $183.8M +60.0% | $114.9M +29.5% | $88.7M -0.6% | $89.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | $302.6M -31.0% | $438.6M -35.1% | $675.5M +30.2% | $518.7M +4.3% | $497.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 8.8% -4.2pp | 13.0% -9.8pp | 22.8% +2.3pp | 20.5% -0.1pp | 20.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $236.0M -6.8% | $253.1M -42.1% | $436.9M +1.0% | $432.7M +4.7% | $413.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 6.9% -0.7pp | 7.5% -7.2pp | 14.7% -2.4pp | 17.1% +0.0pp | 17.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $14.8M +59.1% | $9.3M +24.0% | $7.5M +167.9% | $2.8M +211.1% | $900.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $60.3M +25.9% | $47.9M +192.1% | $16.4M +1.9% | $16.1M +12.6% | $14.3M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$215.0M -348.9% | -$47.9M -143.8% | $109.3M +714.0% | -$17.8M +9.6% | -$19.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $21.0M -89.8% | $205.2M -62.4% | $546.2M +31.6% | $414.9M +5.4% | $393.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 0.6% -5.5pp | 6.1% -12.3pp | 18.4% +2.0pp | 16.4% +0.1pp | 16.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $29.3M -67.9% | $91.4M -22.3% | $117.7M +1.1% | $116.4M +3.0% | $113.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$8.6M -107.6% | $113.1M -73.5% | $427.2M +44.0% | $296.6M +7.0% | $277.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -0.3% -3.6pp | 3.4% -11.1pp | 14.4% +2.7pp | 11.7% +0.3pp | 11.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -119.7% | $1 -74.0% | $3 +46.0% | $2 +9.3% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -119.7% | $1 -73.8% | $3 +45.7% | $2 +9.9% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $151.8M +1.9% | $149.0M +1.8% | $146.4M -1.5% | $148.6M -1.8% | $151.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $151.8M +1.5% | $149.5M +1.6% | $147.2M -1.5% | $149.4M -2.3% | $152.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.20B
Krystal Biotech, Inc.
NASDAQ:KRYS
$9.39B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.64B
Glaukos Corporation
NYSE:GKOS
$7.44B
Teleflex Incorporated
NYSE:TFX
$5.78B
Chemed Corporation
NYSE:CHE
$5.59B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.83B
Merit Medical Systems, Inc.
NASDAQ:MMSI
$3.97B
iRhythm Technologies, Inc.
NASDAQ:IRTC
$3.72B
TransMedics Group, Inc.
NASDAQ:TMDX
$2.51B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does BRKR generate?
Bruker Corporation (BRKR) reported $3.44B of revenue in fiscal 2025.
Is BRKR profitable?
Bruker Corporation (BRKR) reported -$8,600,000.00 of net income, with a net margin of -0.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.